Cerebellar and afferent ataxias

CONTINUUM Lifelong Learning in Neurology

Volumn 19, Issue 5, 2013, Pages 1312-1343

  Pandolfo, Massimo ^a   Manto, Mario ^b  

^a ERASME HOSPITAL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHENODEOXYCHOLIC ACID; DEFERIPRONE; DNA; IDEBENONE; IMMUNOGLOBULIN; MIGLUSTAT; UBIDECARENONE;

AFFERENT ATAXIA; ATAXIA; AUTOIMMUNITY; BODY POSTURE; CEREBELLAR ATAXIA; CLINICAL ASSESSMENT; COGNITIVE DEFECT; DNA SEQUENCE; EYE MOVEMENT DISORDER; FRIEDREICH ATAXIA; GAIT; GENETIC SCREENING; HEREDITARY ATAXIA; HUMAN; LIMB MOVEMENT; MOTONEURON; NEUROIMAGING; NIEMANN PICK DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSCILLATION; PERIPHERAL NERVE; POINT MUTATION; PSYCHOGENIC ATAXIA; REVIEW; SENSORY NEUROPATHY; SPEECH DISORDER; SPINAL CORD; SPINAL GANGLION; SPINOCEREBELLAR DEGENERATION; VESTIBULOOCULAR REFLEX;

ADULT; AGED; ATAXIA; CENTRAL NERVOUS SYSTEM AGENTS; CEREBELLAR ATAXIA; DIAGNOSIS, DIFFERENTIAL; EXERCISE THERAPY; FEMALE; GAIT ATAXIA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; PEDIGREE;

EID: 84885580848     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000436158.39285.22     Document Type: Review

References (94)

1. Macefield VG, Norcliffe-Kaufmann L, Gutié rrez J, et al. Can loss of muscle spindle afferents explain the ataxic gait in Riley-Day syndrome? Brain 2011;134(pt 11): 3198-3208.
2. Manto MU. Cerebellar disorders: a practical approach to diagnosis and management. New York, NY: Cambridge University Press, 2010.
3. Kheradmand A, Zee DS. Cerebellum and ocular motor control. Front Neurol 2011;2:53.
4. Matsui M, Tomimoto H, Sano K, et al. Paroxysmal dysarthria and ataxia after midbrain infarction. Neurology 2004; 63(2):345-347. (Pubitemid 38971139)
5. Holmes G. The cerebellum of man. Brain 1939;62:1-30.
6. Chae JH, Kim SK, Wang KC, et al. Hemifacial seizure of cerebellar ganglioglioma origin: seizure control by tumor resection. Epilepsia 2001;42(9):1204-1207. (Pubitemid 32947943)
7. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain 1998; 121(pt 4):561-579. (Pubitemid 28162120)
8. Schmahmann JD, Weilburg JB, Sherman JC. The neuropsychiatry of the cerebellumV insights from the clinic. Cerebellum 2007; 6(3):254-267.
9. Haines DE, Dietrichs E, Mihailoff GA, McDonald EF. The cerebellar-hypothalamic axis: basic circuits and clinical observations. Int Rev Neurobiol 1997;41:83-107. (Pubitemid 127826222)
10. Sghirlanzoni A, Pareyson D, Lauria G. Sensory neuron diseases. Lancet Neurol 2005;4(6):349-361. (Pubitemid 40720031)
11. Orr HT. Cell biology of spinocerebellar ataxia. J Cell Biol 2012;197(2):167-177.
12. Duyckaerts C, Durr A, Cancel G, Brice A. Nuclear inclusions in spinocerebellar ataxia type 1. Acta Neuropathol 1999;97(2): 201-207. (Pubitemid 29134551)
13. Holmberg M, Duyckaerts C, Durr A, et al. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet 1998;7(5):913-918. (Pubitemid 28221256)
14. Pang JT, Giunti P, Chamberlain S, et al. Neuronal intranuclear inclusions in SCA2: a genetic, morphological and immunohistochemical study of two cases. Brain 2002;125(pt 3):656-663. (Pubitemid 34194418)
15. Fujigasaki H, Uchihara T, Koyano S, et al. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains. Exp Neurol 2000;165(2):248-256.
16. Klement IA, Skinner PJ, Kaytor MD, et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998; 95(1):41-53. (Pubitemid 28458023)
17. Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431(7010):805-810. (Pubitemid 39434070)
18. Bowman AB, Lam YC, Jafar-Nejad P, et al. Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nat Genet 2007;39(3): 373-379. (Pubitemid 46328494)
19. Abou-Sleymane G, Chalmel F, Helmlinger D, et al. Polyglutamine expansion causes neurodegeneration by altering the neuronal differentiation program. Hum Mol Genet 2006;15(5):691-703. (Pubitemid 43264694)
20. Yamanaka T, Nukina N. Transcription factor sequestration by polyglutamine proteins. Methods Mol Biol 2010;648:215-229.
21. Mao R, Aylsworth AS, Potter N, et al. Childhood-onset ataxia: testing for large CAG-repeats in SCA2 and SCA7. Am J Med Genet 2002;110(4):338-345. (Pubitemid 34701048)
22. Kobayashi H, Abe K, Matsuura T, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet 2011;89(1):121-130.
23. Sato N, Amino T, Kobayashi K, et al. Spinocerebellar ataxia type 31 is associated with ''inserted'' penta-nucleotide repeats containing (TGGAA)n. Am J Hum Genet 2009;85(5):544-557.
24. Stevanin G, Herman A, Durr A, et al. Are (CTG)n expansions at the SCA8 locus rare polymorphisms? Nat Genet 2000;24(3): 213-215.
25. Moseley ML, Zu T, Ikeda Y, et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat Genet 2006;38(7): 758-769. (Pubitemid 43980596)
26. Goetz SC, Liem KF, Anderson KV. The spinocerebellar ataxia-associated gene Tau tubulin kinase 2 controls the initiation of ciliogenesis. Cell 2012;151(4):847-858.
27. Duarri A, Jezierska J, Fokkens M, et al. Mutations in potassium channel kcnd3 cause spinocerebellar ataxia type 19. Ann Neurol 2012;72(6):870-880.
28. Lee Y-C, Durr A, Majczenko K, et al. Mutations in KCND3 cause spinocerebellar ataxia type 22. Ann Neurol 2012;72(6): 859-869.
29. Bourassa CV, Meijer IA, Merner ND, et al. VAMP1 mutation causes dominant hereditary spastic ataxia in Newfoundland families. Am J Hum Genet 2012;91(3):548-552.
30. Verbeek DS, van de Warrenburg BP. Genetics of the dominant ataxias. Semin Neurol 2011;31(5):461-469.
31. Globas C, Montcel du ST, Baliko L, et al. Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Mov Disord 2008;23(15): 2232-2238.
32. Shan DE, Soong BW, Sun CM, Lee SJ, et al. Spinocerebellar ataxia type 2 presenting as familial levodopa-responsive parkinsonism. Ann Neurol 2001;50(6):812-815.
33. Van Damme P, Veldink JH, van Blitterswijk M, et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 2011;76(24): 2066-2072.
34. van Alfen N, Sinke RJ, Zwarts MJ, et al. Intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype. Ann Neurol 2001;49(6):805-807.
35. Visser JE, Bloem BR, van de Warrenburg BPC. PRKCG mutation (SCA-14) causing a Ramsay Hunt phenotype. Mov Disord 2007;22(7): 1024-1026. (Pubitemid 46999303)
36. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 2010;9(9):885-894.
37. Schulz JB, Borkert J, Wolf S, et al. Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. Neuroimage 2010;49(1):158-168.
38. Reetz K, Costa AS, Mirzazade S, et al. Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain 2013;136(pt 3):905-917.
39. Anheim M, Tranchant C, Koenig M. The autosomal recessive cerebellar ataxias. N Engl J Med 2012;366(7):636-646.
40. Anheim M, Fleury M, Monga B, et al. Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management. Neurogenetics 2010;11(1):1-12.
41. Hammer MB, Eleuch-Fayache G, Schottlaender LV, et al. Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticity. Am J Hum Genet 2013;92(2): 245-251.
42. Martin E, Schu? le R, Smets K, et al. Loss of function of glucocerebrosidase GBA2 is responsible for motor neuron defects in hereditary spastic paraplegia. Am J Hum Genet 2013;92(2):238-244.
43. Guergueltcheva V, Azmanov DN, Angelicheva D, et al. Autosomal-recessive congenital cerebellar ataxia is caused by mutations in metabotropic glutamate receptor 1. Am J Hum Genet 2012;91(3): 553-564.
44. Doi H, Yoshida K, Yasuda T, et al. Exome sequencing reveals a homozygous SYT14 mutation in adult-onset, autosomalrecessive spinocerebellar ataxia with psychomotor retardation. Am J Hum Genet 2011;89(2):320-327.
45. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271(5254): 1423-1427. (Pubitemid 26089479)
46. Schmucker S, Puccio H. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches. Hum Mol Genet 2010;19(R1):R103Y-110.
47. Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006;2(10):551-558. (Pubitemid 44413238)
48. Cossée M, Durr A, Schmitt M, et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999;45(2): 200-206. (Pubitemid 29072366)
49. Pandolfo M. Drug insight: antioxidant therapy in inherited ataxias. Nat Clin Pract Neurol 2008;4(2):86-96. (Pubitemid 351248066)
50. Durr A, Cossée M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996; 335(16):1169-1175. (Pubitemid 26339770)
51. Montermini L, Richter A, Morgan K, et al. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol 1997;41(5):675-682. (Pubitemid 27212663)
52. Apartis E, Blancher A, Meissner WG, et al. FXTAS: new insights and the need for revised diagnostic criteria. Neurology 2012;79(18):1898-1907.
53. Sattar S, Gleeson JG. The ciliopathies in neuronal development: a clinical approach to investigation of Joubert syndrome and Joubert syndrome-related disorders. Dev Med Child Neurol 2011;53(9): 793-798.
54. Rotthier A, Baets J, De Vriendt E, et al. Genes for hereditary sensory and autonomic neuropathies: a genotype-phenotype correlation. Brain 2009;132(pt 10): 2699-2711.
55. Rajadhyaksha AM, Elemento O, Puffenberger EG, et al. Mutations in FLVCR1 cause posterior column ataxia and retinitis pigmentosa. Am J Hum Genet 2010;87(5): 643-654.
56. Van Goethem G, Martin JJ, Dermaut B, et al. Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. Neuromuscul Disord 2003;13(2):133-142. (Pubitemid 36140008)
57. Hakonen AH, Heiskanen S, Juvonen V, et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet 2005;77(3): 430-441. (Pubitemid 41192649)
58. Manto M. Toxic agents causing cerebellar ataxias. Handb Clin Neurol 2012;103: 201-213.
59. Laureno R. Nutritional cerebellar degeneration, with comments on its relationship to Wernicke disease and alcoholism. Handb Clin Neurol 2012;103:175-187.
60. Iwasaki Y, Okamoto A, Shoda H, et al. Subacute cerebellar ataxia and atrophy developed in a young woman with systemic lupus erythematosus whose cerebrospinal fluid was positive for antineuronal cell antibody. Lupus 2012;21(3):324-328.
61. Hadjivassiliou M, Boscolo S, Tongiorgi E, et al. Cerebellar ataxia as a possible organ-specific autoimmune disease. Mov Disord 2008;23(10):1370-1377.
62. Honnorat J, Saiz A, Giometto B, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 2001;58(2): 225-230. (Pubitemid 32163159)
63. Manto MU, Laute MA, Aguera M, et al. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 2007;61(6):544-551. (Pubitemid 47068136)
64. Hadjivassiliou M, Sanders DS, Woodroofe N, et al. Gluten ataxia. Cerebellum 2008;7(3): 494-498.
65. Abele M, Schols L, Schwartz S, Klockgether T. Prevalence of antigliadin antibodies in ataxia patients. Neurology 2003;60(10): 1674-1675. (Pubitemid 36618099)
66. Selim M, Drachman DA. Ataxia associated with Hashimoto's disease: progressive non-familial adult onset cerebellar degeneration with autoimmune thyroiditis. J Neurol Neurosurg Psychiatr 2001;71(1): 81-87.
67. Ferracci F, Bertiato G, Moretto G. Hashimoto's encephalopathy: epidemiologic data and pathogenetic considerations. J Neurol Sci 2004;217(2):165-168. (Pubitemid 38056550)
68. Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013;12(3):264-274.
69. Kollensperger M, Geser F, Seppi K, et al. Red flags for multiple system atrophy. Mov Disord 2008;23(8):1093-1099.
70. Manto MU, Habas C. Le cervelet: de la'natomie et la physiologie á la Clinique humaine. Springer, 2013.
71. Tan IYL, de Tilly LN, Gray TA. Hypocupremia: an under recognized cause of subacute combined degeneration. Can J Neurol Sci 2009;36(6):779-782.
72. Hathout L, El-Saden S. Nitrous oxide-induced B12 deficiency myelopathy: perspectives on the clinical biochemistry of vitamin B12. J Neurol Sci 2011;301(1-2):1-8.
73. Vermeer S, Hoischen A, Meijer RPP, et al. Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia. Am J Hum Genet 2010;87(6):813-819.
74. Nanri K, Okita M, Takeguchi M, et al. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia. Intern Med 2009;48(10):783-790.
75. Artuch R, Brea-Calvo G, Briones P, et al. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol Sci 2006;246(1-2):153-158. (Pubitemid 43815358)
76. Bonnot O, Fraidakis MJ, Lucanto R, et al. Cerebrotendinous xanthomatosis presenting with severe externalized disorder: improvement after one year of treatment with chenodeoxycholic acid. CNS Spectr 2010;15(4):231-236.
77. Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007;6(9):765-772. (Pubitemid 47238662)
78. Broccoletti T, Del Giudice E, Amorosi S, et al. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients. Eur J Neurol 2008;15(3): 223-228. (Pubitemid 351257930)
79. Pandolfo M. Treatment of Friedreich's ataxia. Expert Opin Orphan Drugs 2013;1(3): 221-234.
80. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007;6(10):878-886. (Pubitemid 47404985)
81. Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol 2010;67(8):941-947.
82. Lynch DR, Willi SM, Wilson RB, et al. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov Disord 2012;27(8):1026-1033.
83. Kakhlon O, Manning H, Breuer W, et al. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood 2008;112(13):5219-5227.
84. Boddaert N, Le Quan Sang KH, Rotig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007;110(1):401-408. (Pubitemid 47026862)
85. Sturm B, Stupphann D, Kaun C, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest 2005;35(11):711-717. (Pubitemid 41640907)
86. Mariotti C, Fancellu R, Caldarazzo S, et al. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord 2012;27(3):446-449.
87. Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 2008;3(4):e1958.
88. Rai M, Soragni E, Chou CJ, et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One 2010; 5(1):e8825.
89. Sandi C, Pinto RM, Al-Mahdawi S, et al. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol Dis 2011;42(3):496-505.
90. Strupp M, Kalla R, Dichgans M, et al. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 2004;62(9):1623-1625. (Pubitemid 38608211)
91. Yabe I, Sasaki H, Yamashita I, et al. Clinical trial of acetazolamide in SCA6, with assessment using the Ataxia Rating Scale and body stabilometry. Acta Neurol Scand 2001;104(1):44-47. (Pubitemid 32588399)
92. Zesiewicz TA, Greenstein PE, Sullivan KL, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 2012;78(8):545-550.
93. Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010;74(10):839-845.
94. Ilg W, Synofzik M, Brotz D, et al. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 2009;73(22):1823-1830.